Jacobs Levy Equity Management, Inc Akebia Therapeutics, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $25.8 Billion
- Q4 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 1,228,710 shares of AKBA stock, worth $2.62 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,228,710
Previous 2,034,169
39.6%
Holding current value
$2.62 Million
Previous $2.69 Million
14.9%
% of portfolio
0.01%
Previous 0.01%
Shares
31 transactions
Others Institutions Holding AKBA
# of Institutions
128Shares Held
63.3MCall Options Held
50.6KPut Options Held
203K-
Black Rock Inc. New York, NY11.6MShares$24.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$23.2 Million0.0% of portfolio
-
State Street Corp Boston, MA6.3MShares$13.4 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$12.2 Million20.26% of portfolio
-
Geode Capital Management, LLC Boston, MA4.8MShares$10.2 Million0.0% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $392M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...